

This product contains a substance that is not included in the European review programme for existing active substances (Regulation (EU) No 1062/2014). This product cannot therefore benefit from the transitional measures (Article 89 of the BPR), pending approval of the new active substance. The placing on the market of the product is therefore prohibited, while the product has not been authorised according to Regulation (EU) No 528/2012. This Regulation nevertheless provides derogation provisions to authorise a product containing a new active substance, pending approval of the latter (Article 55.2 of the BPR).